Effects of Mulberry Juice on Inflammatory Status and Clinical Symptoms in Patients With General Anxiety Disorder

Systemic Inflammation Clinical Trial

Official title:

Auxiliary Effects of Mulberry Juice on Inflammatory Status and Clinical Symptoms in Patients With General Anxiety Disorder: A Single-Blinded Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03935061
• Other study ID #: N201802079
• Status: Recruiting
• Phase: N/A
• Start date: July 3, 2019
• Est. completion date: May 31, 2021

Study information

• Verified date: April 2019
• Source: Taipei Medical University
• Contact: El-Wui Loh, PhD
• Phone: 886-2-22490088
• Email: lohew[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Anxiety and depression are normally associated with inflammation reactions and interleukin (IL) related pathways are most evidently involved. IL-17A (interleukin 17A) induces psoriasis-like inflammation and depression-like behaviors in animals and can be relieved by using IL-17A antibody. Also, human association studies found that IL-17A and certain downstream ILs are associated with the severity of anxiety. IL-17A is a sentinel cytokine. On binding with interleukin 17A receptor (IL-17RA) and interleukin 17C receptor (IL-27RC), it induces signaling cascades via nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), P38 mitogen-activated protein kinases (p38MAPK) and CCAAT-enhancer-binding proteins (C/EBPs) knots, and stimulates subsequent cell secretions of cytokines and chemokines. Cyanidin 3-O-glucoside, the main anthocyanin component of mulberry, competes with IL-17A to bind its receptors and inhibits subsequent downstream cascades. The investigators plan to use a single-blinded randomized controlled trial to evaluate the auxiliary effect of mulberry juice in general anxiety disorder, including differences in psychiatric symptoms and levels of IL-related markers between the experimental and control groups, and contribution of IL-related genes in the auxiliary effect.

Description:

The etiology, pathogenesis, and pathophysiology of psychiatric disorders are not limited to the brain. Anxiety and depression are normally associated with inflammation reactions and interleukin (IL) related pathways are most evidently involved. Previous animal studies showed that administration of IL-17A induces psoriasis-like inflammation and depression-like behavior, and can be relieved by using IL-17A antibody, while in humans, association studies showed that serum IL-17A and certain downstream ILs are associated with the severity of anxiety. Also, the result of human genetic studies also identified several IL genes associated with anxiety and depression. IL-17A is a sentinel cytokine. On binding with interleukin 17A receptor (IL-17RA) and interleukin 17C receptor (IL-27RC), it induces signaling cascades via nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), P38 mitogen-activated protein kinases (p38MAPK) and CCAAT-enhancer-binding proteins (C/EBPs) knots, and stimulates subsequent cell secretions of cytokines and chemokines. Many studies have demonstrated that consumption of proanthocyanidin-rich or anthocyanin-rich berries, berries juice or other secondary products reduce a variety of inflammation symptoms in humans. However, these berries do not meet a low-cost requirement for general nutritional recommendation and new drug development in Taiwan due to the additional import cost. On the other hand, cyanidin 3-O-glucoside, the main anthocyanin component of local mulberry, competes with IL-17A to bind its receptors and inhibits subsequent downstream cascades. Without interfering the on-going treatment of the patients, this proposal plans to use a single-blinded randomized controlled trial to evaluate the auxiliary effect of mulberry juice in general anxiety disorder, including differences in psychiatric symptoms (anxiety, depression, and functions) and levels of IL-related markers between the experimental and control groups, and contribution of IL-related genes in the auxiliary effect.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 104
• Est. completion date: May 31, 2021
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

• meet the criteria for GAD in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, as their primary diagnosis

Exclusion Criteria:

• severe physical diseases that required intensive care or additional medical attention such as terminal cancer, stroke, and end-stage renal disease

• psychotic symptoms or recent suicide attempts

Related Conditions & MeSH terms

• Anxiety Disorders
• Disease
• General Anxiety Disorders
• Inflammation
• Interleukin
• Systemic Inflammation

Intervention

Other:
• Mulberry juice
On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.

Locations

Country	Name	City	State
Taiwan	Taipei Medical University Shuang Ho Hospital	New Taipei City

Sponsors (1)

Lead Sponsor	Collaborator
Taipei Medical University

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	General Anxiety Disorder-7 items (GAD-7)	GAD-7 measures anxiety status. The questionnaire is self-reported.	5 to 10 minutes
Primary	Patient Health Questionnaire-9 items (PHQ-9)	PHQ-9 measure depression status. This questionnaire is self-reported.	5 to 10 minutes
Primary	World Health Organization Quality of Life - Brief (WHOQOL-BREF)	WHOQOL-BREF measures the quality of life. The questionnaire is self-reported.	5 to 10 minutes
Secondary	Inflammation markers	Inflammation status of the patients are evaluated by measuring CRP, known cytokines (Interleukin- 6 [IL-6], Interleukin-1ß [IL-1ß], tumor necrosis factor-a (TNF-a), granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], and transforming growth factor [TGF-ß]), chemokines (IL-8, GRO-a, and MCP-1), and PGE in sera, in addition to the sentinel molecule IL-17A. All markers are measured by using ELISA assays according to manufacturer instructions.	6 months
Secondary	Inflammation genes	Inflammation genes including CRP, cytokines (IL-6, IL-1ß, TNF-a, G-CSF, GM-CSF, and TGF-ß), chemokines (IL-8, GRO-a, and MCP-1), and PGE in addition to IL-17A, are to be genotyped.	24 months